A former Amgen Inc. employee filed a proposed class action challenging the biotechnology company’s practice of charging ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

If you are wondering whether Amgen’s recent share price puts it on sale or at a premium, and what that really means for your ...

In the latest close session, Amgen (AMGN) was up +1.69% at $355.30. This move outpaced the S&P 500's daily gain of 1.2%. Elsewhere, the Dow gained 1.79%, while the tech-heavy Nasdaq added 1.52%. Prior ...

Amgen Inc. (NASDAQ:AMGN) is included among the 10 Healthcare Stocks with Highest Dividends. On April 13, UBS lifted its price ...

Amgen's Tepezza became the first drug approved by the FDA for thyroid eye disease (TED) in 2020, and the company is now looking to extend its role with a new, more patient-friendly formulation. The ...

Global drug maker Pfizer (PFE) and biotech firm Amgen (AMGN), each valued at over HK$1T ($153B), are among 22 strategic ...

With another year of double-digit revenue growth in the books, Amgen’s longtime helmsman Robert Bradway continues to sit ...

Delve into the pipeline strategy of major biotech Amgen, which is increasingly diversifying its growth engines.

The competition for treatments in the weight-loss market is heating up. Amgen is currently working on a promising anti-obesity medicine. There are plenty of other excellent reasons to buy the stock ...

Evidence gaps include limited topline safety granularity, unknown long-term follow-up and retreatment rates, and lack of ...

Amgen announced 52-week results from a phase 2 trial with its weight-management candidate, MariTide. The results Amgen posted don't appear very competitive with Eli Lilly's weight management drug, ...